<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14771">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02914600</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-419-3896</org_study_id>
    <secondary_id>2016-002763-34</secondary_id>
    <nct_id>NCT02914600</nct_id>
  </id_info>
  <brief_title>Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease</brief_title>
  <acronym>DIVERSITYLTE</acronym>
  <official_title>A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects With Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to observe the long-term safety of filgotinib in
      adults who have completed or met protocol specified efficacy discontinuation criteria in a
      prior Gilead-sponsored filgotinib treatment study in Crohn's disease (CD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2017</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Safety Profile of Filgotinib Evaluated by the Percentage of Participants Experiencing Adverse Events and Abnormal Clinical Laboratory Tests</measure>
    <time_frame>Up to 144 weeks plus 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in PRO2 Scores</measure>
    <time_frame>Baseline and up to 144 weeks</time_frame>
    <description>PRO2 are patient reported outcomes consisting of 2 items: abdominal pain severity and liquid stool frequency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Crohn's Disease Activity Index (CDAI) Scores</measure>
    <time_frame>Baseline and up to 144 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Filgotinib Dose A (blinded dosing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Filgotinib dose A + placebo to match filgotinib dose B for up to 144 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Filgotinib Dose B (blinded dosing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Filgotinib dose B + placebo to match filgotinib dose A for up to 144 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (blinded dosing)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for up to 144 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Filgotinib Dose A (open-label)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Filgotinib dose A for up to 144 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Filgotinib Dose B (open-label)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Filgotinib dose B for up to 144 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgotinib</intervention_name>
    <description>Tablet(s) administered orally once daily</description>
    <arm_group_label>Filgotinib Dose A (blinded dosing)</arm_group_label>
    <arm_group_label>Filgotinib Dose B (blinded dosing)</arm_group_label>
    <arm_group_label>Filgotinib Dose A (open-label)</arm_group_label>
    <arm_group_label>Filgotinib Dose B (open-label)</arm_group_label>
    <other_name>GS-6034</other_name>
    <other_name>GLPG0634</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet(s) administered orally once daily</description>
    <arm_group_label>Filgotinib Dose A (blinded dosing)</arm_group_label>
    <arm_group_label>Filgotinib Dose B (blinded dosing)</arm_group_label>
    <arm_group_label>Placebo (blinded dosing)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Must have the ability to understand and sign a written informed consent form (ICF),
             which must be obtained prior to initiation of study procedures associated with this
             trial

          -  Must have met all eligibility criteria from a Gilead-sponsored CD parent protocol

          -  Females of childbearing potential must have a negative pregnancy test at Day 1

          -  Males and females of childbearing potential who engage in heterosexual intercourse
             must agree to use protocol specified method(s) of contraception as described in the
             study protocol, for the duration described

          -  Willingness to refrain from live or attenuated vaccines during the study and for 12
             weeks after last dose of study drug

        Key Exclusion Criteria:

          -  Known hypersensitivity to the study drug

          -  Any chronic medical condition (including, but not limited to, cardiac or pulmonary
             disease, alcohol or drug abuse) that, in the opinion of the Investigator, would make
             the individual unsuitable for the study or would prevent compliance with the study
             protocol

          -  Males or females of reproductive potential who are unwilling to abide by
             protocol-specified contraceptive methods as defined in the study protocol

          -  Use of prohibited medications as outlined in the study protocol

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Study Team</last_name>
    <email>419-3896study@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Digestive Health Specialists of SE</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UF Health IBD Research</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ocean Blue Medical Research Center, Inc</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Pharma CR, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33147</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Group of Naples</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Delta Research Partners, LLC</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina's GI Research, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Paramount Medical Research &amp; Consulting, LLC</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Options Health Research LLC</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ClinSearch, LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Center of the MidSouth, P.C.</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Research of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consultants</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research, LLC</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emeritas Research Group LLC</name>
      <address>
        <city>Leesburg</city>
        <state>Virginia</state>
        <zip>20176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Glasgow Royal Infirmary, Clinical Research Facility</name>
      <address>
        <city>Glasgow</city>
        <zip>G31 2ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Glasgow Clinical Research Facility</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Norfolk &amp; Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Helens &amp; Knowsley Teaching Hospitals NHS Trust</name>
      <address>
        <city>Prescot</city>
        <zip>L35 5DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>September 22, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
